{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:22:46Z","timestamp":1792783366297,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Project of State Key Laboratory of Radiation Medicine and Protection, Soochow University","award":["No.GZK12025037"],"award-info":[{"award-number":["No.GZK12025037"]}],"id":[{"id":"https:\/\/ror.org\/02av90z31","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03440-1","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:00:45Z","timestamp":1791460845000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nutritional inflammatory hematological risk index predicts clinical outcomes in patients with advanced NSCLC receiving immunotherapy"],"prefix":"10.1007","volume":"43","author":[{"given":"Yiqing","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxian","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"issue":"3","key":"3440_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2022;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"10026","key":"3440_CR2","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/s0140-6736(15)01125-3","volume":"387","author":"R Rosell","year":"2016","unstructured":"Rosell R, Karachaliou N. Large-scale screening for somatic mutations in lung cancer. Lancet. 2016;387(10026):1354\u20136. https:\/\/doi.org\/10.1016\/s0140-6736(15)01125-3.","journal-title":"Lancet"},{"issue":"4","key":"3440_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2174\/0115665232340926241105064739","volume":"25","author":"CL Li","year":"2025","unstructured":"Li CL, Ma XY, Yi P. The role of immunotherapy in lung cancer treatment: current strategies, future directions, and insights into metastasis and immune microenvironment. Curr Gene Ther. 2025;25(4):453\u201366. https:\/\/doi.org\/10.2174\/0115665232340926241105064739.","journal-title":"Curr Gene Ther"},{"key":"3440_CR4","doi-asserted-by":"publisher","unstructured":"Xie M, et al. Transcriptomic Signatures in TP53 Positive and Negative Tumor Samples in NSCLC. Curr Gene Ther 2025.https:\/\/doi.org\/10.2174\/0115665232357300250805021330","DOI":"10.2174\/0115665232357300250805021330"},{"issue":"11","key":"3440_CR5","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1016\/j.jtho.2023.09.059","volume":"18","author":"C Zhou","year":"2023","unstructured":"Zhou C, et al. OA090.6 IMpower151: Phase III Study of Atezolizumab + Bevacizumab + Chemotherapy in 1L Metastatic Nonsquamous NSCLC. J Thoracic Oncol. 2023;18(11):S64\u20135. https:\/\/doi.org\/10.1016\/j.jtho.2023.09.059.","journal-title":"J Thoracic Oncol"},{"issue":"22","key":"3440_CR6","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093\u2013104. https:\/\/doi.org\/10.1056\/NEJMoa1801946.","journal-title":"N Engl J Med"},{"issue":"24","key":"3440_CR7","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288\u2013301. https:\/\/doi.org\/10.1056\/NEJMoa1716948.","journal-title":"N Engl J Med"},{"key":"3440_CR8","doi-asserted-by":"publisher","DOI":"10.2174\/1874467217666230721123554","volume":"17","author":"XJ Qian","year":"2024","unstructured":"Qian XJ, et al. The mediating role of miR-451\/ETV4\/MMP13 signaling axis on epithelialmesenchymal transition in promoting non-small cell lung cancer progression. Curr Mol Pharmacol. 2024;17:e210723218988. https:\/\/doi.org\/10.2174\/1874467217666230721123554.","journal-title":"Curr Mol Pharmacol"},{"issue":"2","key":"3440_CR9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2174\/0115665232292768240503050508","volume":"25","author":"A Beigi","year":"2025","unstructured":"Beigi A, et al. Lipid-based nanocarriers for targeted gene delivery in lung cancer therapy: exploring a novel therapeutic paradigm. Curr Gene Ther. 2025;25(2):92\u2013112. https:\/\/doi.org\/10.2174\/0115665232292768240503050508.","journal-title":"Curr Gene Ther"},{"issue":"4","key":"3440_CR10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.scib.2023.12.046","volume":"69","author":"SY Maggie Liu","year":"2024","unstructured":"Maggie Liu SY, et al. PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial. Sci Bull (Beijing). 2024;69(4):535\u201343. https:\/\/doi.org\/10.1016\/j.scib.2023.12.046.","journal-title":"Sci Bull (Beijing)"},{"issue":"4","key":"3440_CR11","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/s1470-2045(24)00040-8","volume":"25","author":"BHL Goulart","year":"2024","unstructured":"Goulart BHL, et al. Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis. Lancet Oncol. 2024;25(4):455\u201362. https:\/\/doi.org\/10.1016\/s1470-2045(24)00040-8.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3440_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-51844-8","volume":"14","author":"Y Yang","year":"2024","unstructured":"Yang Y, et al. Clinical role of pretreatment albumin-to-alkaline phosphatase ratio in lung cancer: a meta-analysis. Sci Rep. 2024;14(1):1166. https:\/\/doi.org\/10.1038\/s41598-024-51844-8.","journal-title":"Sci Rep"},{"issue":"21","key":"3440_CR13","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/jco.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck M, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50. J Clin Oncol. 2021;39(21):2339\u201349. https:\/\/doi.org\/10.1200\/jco.21.00174.","journal-title":"J Clin Oncol"},{"issue":"10","key":"3440_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103727","volume":"9","author":"J Wang","year":"2024","unstructured":"Wang J, et al. Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial. ESMO Open. 2024;9(10):103727. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103727.","journal-title":"ESMO Open"},{"issue":"9","key":"3440_CR15","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","volume":"16","author":"C Zhou","year":"2021","unstructured":"Zhou C, et al. Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12). J Thorac Oncol. 2021;16(9):1501\u201311. https:\/\/doi.org\/10.1016\/j.jtho.2021.04.011.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"3440_CR16","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/j.jtho.2020.09.028","volume":"15","author":"Y Yang","year":"2020","unstructured":"Yang Y, Zhou H, Zhang L. Response to letter to the editor: efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (ORIENT-11). J Thorac Oncol. 2020;15(12):e191\u20132. https:\/\/doi.org\/10.1016\/j.jtho.2020.09.028.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"3440_CR17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/s2213-2600(20)30365-9","volume":"9","author":"C Zhou","year":"2021","unstructured":"Zhou C, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2021;9(3):305\u201314. https:\/\/doi.org\/10.1016\/s2213-2600(20)30365-9.","journal-title":"Lancet Respir Med"},{"key":"3440_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.859938","volume":"12","author":"K Miao","year":"2022","unstructured":"Miao K, et al. Real-world data of different immune checkpoint inhibitors for non-small cell lung cancer in China. Front Oncol. 2022;12:859938. https:\/\/doi.org\/10.3389\/fonc.2022.859938.","journal-title":"Front Oncol"},{"issue":"1","key":"3440_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08096-w","volume":"21","author":"J Lester","year":"2021","unstructured":"Lester J, et al. Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom. BMC Cancer. 2021;21(1):515. https:\/\/doi.org\/10.1186\/s12885-021-08096-w.","journal-title":"BMC Cancer"},{"key":"3440_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102031","volume":"87","author":"G Pasello","year":"2020","unstructured":"Pasello G, et al. Real world data in the era of immune checkpoint inhibitors (ICIs): increasing evidence and future applications in lung cancer. Cancer Treat Rev. 2020;87:102031. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102031.","journal-title":"Cancer Treat Rev"},{"issue":"17","key":"3440_CR21","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1507643.","journal-title":"N Engl J Med"},{"issue":"10183","key":"3440_CR22","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/s0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819\u201330. https:\/\/doi.org\/10.1016\/s0140-6736(18)32409-7.","journal-title":"Lancet"},{"issue":"19","key":"3440_CR23","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1606774.","journal-title":"N Engl J Med"},{"issue":"14","key":"3440_CR24","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383(14):1328\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1917346.","journal-title":"N Engl J Med"},{"key":"3440_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.962947","volume":"12","author":"C Martin","year":"2022","unstructured":"Martin C, Enrico D. Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer. Front Oncol. 2022;12:962947. https:\/\/doi.org\/10.3389\/fonc.2022.962947.","journal-title":"Front Oncol"},{"issue":"22","key":"3440_CR26","doi-asserted-by":"publisher","first-page":"6335","DOI":"10.1016\/j.cell.2025.08.013","volume":"188","author":"Y Han","year":"2025","unstructured":"Han Y, et al. Tumors hijack macrophages for iron supply to promote bone metastasis and anemia. Cell. 2025;188(22):6335-6354.e26. https:\/\/doi.org\/10.1016\/j.cell.2025.08.013.","journal-title":"Cell"},{"issue":"6","key":"3440_CR27","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.ccell.2022.04.018","volume":"40","author":"H Long","year":"2022","unstructured":"Long H, et al. Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1\/PD-L1 treatment efficacy. Cancer Cell. 2022;40(6):674\u201393. https:\/\/doi.org\/10.1016\/j.ccell.2022.04.018.","journal-title":"Cancer Cell"},{"issue":"21","key":"3440_CR28","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, et al. Nivolumab plus Ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1910231.","journal-title":"N Engl J Med"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03440-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03440-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03440-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:00:47Z","timestamp":1791460847000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03440-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["3440"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03440-1","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the Ethics Committee of the Second Affiliated Hospital of Soochow University for retrospective research. Ethics review decision number: JD-HG-2024-052.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"329"}}